A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation

Antibody-induced complement activation may cause injury of the neuromuscular junction (NMJ) and is thus considered as a primary pathogenic factor in human myasthenia gravis (MG) and animal models of experimental autoimmune myasthenia gravis (EAMG). In this study, we tested whether CRIg/FH, a targete...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Jie, Zhao, Rui, Yan, Chong, Luo, Sushan, Xi, Jianying, Ding, Peipei, Li, Ling, Hu, Weiguo, Zhao, Chongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825366/
https://www.ncbi.nlm.nih.gov/pubmed/35154091
http://dx.doi.org/10.3389/fimmu.2022.746068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825366/
https://www.ncbi.nlm.nih.gov/pubmed/35154091
http://dx.doi.org/10.3389/fimmu.2022.746068

Ejemplares similares